Company No: 13060328 (England and Wales)

Contents

• Company Information
• Balance Sheet
• Notes to the Financial Statements

DIRECTORS	Benjamin Birrell
	Katie Louise Birrell
	Dawn Dowds
	Beverley Jayne Elliot (Resigned 24 May 2025)
	Zeeus Roy Thomas Stone

SECRETARY

Benjamin Birrell

REGISTERED OFFICE	Barn 1 Rookery Meade Farm Beyton Road
	Drinkstone
	Bury St. Edmunds
	IP30 9SS
	United Kingdom

COMPANY NUMBER

13060328 (England and Wales)

CHARTERED ACCOUNTANTS	Gascoynes
	Gascoyne House
	Moseleys Farm Business Centre
	Fornham All Saints
	Bury St Edmunds
	Suffolk
	IP28 6JY

	Note	2025		2024
		£		£
Fixed assets
Tangible assets	3	3,508		0
Investments	4	480		480
		3,988		480
Current assets
Stocks	5	0		214,212
Debtors	6	119,423		366,164
Cash at bank and in hand		12,007		15,700
		131,430		596,076
Creditors: amounts falling due within one year	7	( 327,767)		( 32,157)
Net current (liabilities)/assets		(196,337)		563,919
Total assets less current liabilities		(192,349)		564,399
Net (liabilities)/assets		( 192,349)		564,399
Capital and reserves
Called-up share capital	8	1,813		1,600
Profit and loss account		( 194,162 )		562,799
Total shareholders' (deficit)/funds		( 192,349)		564,399

For the financial year ending 31 December 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• The members have not required the Company to obtain an audit of its financial statements for the financial year in accordance with section 476;
• The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements; and
• These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime and a copy of the Statement of Income and Retained Earnings has not been delivered.

The financial statements of Haelan Pharmaceuticals Limited (registered number: 13060328) were approved and authorised for issue by the Board of Directors on 25 August 2026. They were signed on its behalf by:

Dawn Dowds Director

1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial year, unless otherwise stated.

General information and basis of accounting

Haelan Pharmaceuticals Limited (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Barn 1 Rookery Meade Farm Beyton Road, Drinkstone, Bury St. Edmunds, IP30 9SS, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Tangible fixed assets

Tangible fixed assets are stated at cost or valuation, net of depreciation and any provision for impairment. Depreciation is provided on all tangible fixed assets, other than investment property and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a straight-line or reducing balance basis over its expected useful life, as follows:

Plant and machinery etc.

25 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

Leases

The Company as lessee
Assets held under finance leases, hire purchase contracts and other similar arrangements, which confer rights and obligations similar to those attached to owned assets, are capitalised as tangible fixed assets at the fair value of the leased asset (or, if lower, the present value of the minimum lease payments as determined at the inception of the lease) and are depreciated over the shorter of the lease terms and their useful lives. The capital elements of future lease obligations are recorded as liabilities, while the interest elements are charged to the Statement of Income and Retained Earnings over the period of the leases to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals under operating leases are charged on a straight-line basis over the lease term, even if the payments are not made on such a basis. Benefits received and receivable as an incentive to sign an operating lease are similarly spread on a straight-line basis over the lease term.

The Company as lessor
Amounts due from lessees under finance leases are recognised as receivables at the amount of the Company's net investment in the leases. Finance lease income is allocated to accounting periods so as to reflect a constant periodic rate of return on the Company's net investment outstanding in respect of leases.

Rental income from operating leases is recognised on a straight-line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight-line basis over the lease term.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Balance Sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to sell, which is equivalent to the net realisable value. Cost includes materials, direct labour and an attributable proportion of manufacturing overheads based on normal levels of activity. Cost is calculated using the FIFO (first-in, first-out) method. Provision is made for obsolete, slow-moving or defective items where appropriate.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument.

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

Financial assets and liabilities are only offset in the Balance Sheet when, and only when there exists a legally enforceable right to set off the recognised amounts and the Company intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

2. Employees

	2025		2024
	Number		Number
Monthly average number of persons employed by the Company during the year, including directors	11		6

3. Tangible assets

	Plant and machinery etc.		Total
	£		£
Cost
At 01 January 2025	0		0
Additions	4,158		4,158
At 31 December 2025	4,158		4,158
Accumulated depreciation
At 01 January 2025	0		0
Charge for the financial year	650		650
At 31 December 2025	650		650
Net book value
At 31 December 2025	3,508		3,508
At 31 December 2024	0		0

4. Fixed asset investments

	Other investments		Total
	£		£
Cost or valuation before impairment
At 01 January 2025	480		480
At 31 December 2025	480		480
Carrying value at 31 December 2025	480		480
Carrying value at 31 December 2024	480		480

5. Stocks

	2025		2024
	£		£
Stocks	0		214,212

6. Debtors

	2025		2024
	£		£
Amounts owed by Group undertakings	91,099		307,508
Other debtors	28,324		58,656
	119,423		366,164

7. Creditors: amounts falling due within one year

	2025		2024
	£		£
Trade creditors	29,905		10,781
Amounts owed to Group undertakings	30,976		0
Other taxation and social security	18,861		19,152
Other creditors	248,025		2,224
	327,767		32,157

8. Called-up share capital

	2025		2024
	£		£
Allotted, called-up and fully-paid
1,259 Ordinary - A shares of £ 1.00 each (2024: nil shares)	1,259		0
341 Ordinary - B shares of £ 1.00 each (2024: nil shares)	341		0
213 Ordinary - C shares of £ 1.00 each (2024: nil shares)	213		0
Nil Ordinary shares (2024: 1,600 shares of £ 1.00 each)	0		1,600
	1,813		1,600

9. Related party transactions

Transactions with entities in which the entity itself has a participating interest

	2025		2024
	£		£
Balances owed by subsidiaries - Pura Health Limited	0		98,723
Balances owed by subsidiaries - Greenleaf Processing Limited	91,099		208,786
Amounts owed to subsidiaries - Bury Shop	(30,976)		0

Transactions with the entity's directors

	2025		2024
	£		£
Amount owed to Director - D Dowds	(25,717)		1,044
Amount owed by Director - T Bolding	0		28,399
Amount owed to Director - Z Stone	(30,000)		786
Amount owed to Director - B Birrell	(24,415)		7,866
Amounts owed to Director - K Birrell	(114,592)		0